Investor's Business Daily on MSN

Dow Jones' Merck tops forecasts, but growth products come up mixed

Merck easily topped expectations Thursday, delivering lighter-than-expected losses as Keytruda handily beat sales forecasts.
Nasdaq

Will the FDA's Nod for Subcutaneous Keytruda Ease Merck's Headwinds?

Merck MRK announced that the FDA has approved the subcutaneous (under the skin or SC) formulation of its blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab). This version, which will be marketed as ...

Regeneron faces Wall Street downgrades after high-profile melanoma drug fails to beat Merck's Keytruda

Regeneron Pharmaceuticals Inc (NASDAQ:REGN), the US biotech group, fell premarket trading on Monday after its most closely ...
Investopedia

Merck Gets FDA Approval to Expand Use of Its Top-Selling Drug, Keytruda

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...